About us

Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.


Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.


Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.

LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert antiviral, inflammation-controlling, and antifibrotic properties.    

News & Events

Laurent Pharmaceuticals to present at the North American Cystic Fibrosis Conference, November 3-5, 2022 – Philadelphia, PA

Laurent Pharma to participate to BIO International Convention,
June 13-16, 2022 – San Diego, CA

Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022